ClinicalTrials.gg
Active, not recruitingNCT06238843G-HOPE-001Updated May 13, 2026

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

A Phase 3 interventional study of Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI) and IBI343 in Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 95 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)

02

Conditions studied

  • Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to sign a written Form(ICF) and to comply with protocol-specified visits and related procedures.
  2. Has histopathologically confirmed unresectable locally advanced or adenocarcinoma of the gastric/gastroesophageal junction (G/GEJ AC).
  3. Has received and progressed on at least 2 (anti-PD-(L)1 in combination with platinum or fluoropyrimidines, paclitaxel/docetaxel, irinotecan). A prior (neo) systemic therapy that ended within 6 months prior to disease relapse is defined as the first line therapy. The subject has ≤ 4 prior lines of systemic therapy.
  4. Has histopathologically confirmed CLDN18.2-positive disease.
  5. Is a man or woman of 18 years of age or older at the time of signing the ICF.
  6. Has an (ECOG) performance status (PS) of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  1. Has -positive (defined as immunohistochemistry [IHC] 3+, or IHC 2+ and positive by in situ hybridization) disease.
  2. Is currently participating in another interventional clinical study, except when the subject is during survival follow-up of an interventional clinical study.
  3. Has a history of treatment with topoisomerase inhibitorbased antibody-drug conjugate(s).
  4. Has received the last dose of an anti-cancer therapy (including traditional Chinese medicine indicated for gastric cancer in the package insert, but excluding herbal prescriptions) within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study treatment.
  5. Plans to receive other anti-cancer therapy during treatment with the study drug (palliative radiotherapy for symptomatic (e.g., pain) relief that does not affect response assessment is allowed).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
464 participants (actual)

Study arms

  • Active comparator
    Active Comparator: control arm

    There are three drugs ( irinotecan, paclitaxel,or FTD/TPI (only are applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment)) in active contral arm, the subjects will receive the drug based on investigator's choice

    Drug: Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI)

  • Experimental
    IBI343 monotherapy

    IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .

    Drug: IBI343

Interventions

  • DrugIrinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI)

    Drugs: Irinotecan Subjects in the control arm will receive irnotecan 150mg/m2 IV D1, D15, Q4W in 4-weeks cycles. Drugs: Paclitaxel Subjects in the control arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles, Drugs:FTD/TPI Subjects in the control arm will receive FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment).

  • DrugIBI343

    Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .

    Also known as: Arcotatug Tavatecan

06

What researchers measure

Primary outcomes

  1. progression free survival(PFS)

    Progression-free survival (PFS) is defined as the time from random assignment in the trial to disease progression or death from any cause.

    Time frame: within approximately 20 months

  2. overall survival(OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause.

    Time frame: within approximately 26 months

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of subjects in the analysis population who achieve confirmed objective response (CR or PR) as assessed by the IRRC per RECIST v1.1.

    Time frame: within approximately 20 months

  2. disease control rate (DCR)

    DCR is defined as the proportion of subjects in the analysis population who achieve disease control (CR, PR, or SD) as determined by the IRRC per RECIST v1.1 criteria.

    Time frame: within approximately 20 months

  3. duration of response (DoR)

    DoR is defined as the time from the first CR or PR to disease progression or death from any cause, whichever occurs first for subjects with ORR as assessed by IRRC per RECIST v1.1 criteria.

    Time frame: within approximately 20 months

  4. time to response (TTR)

    TTR is defined as the time from randomization to the first CR or PR for subjects with ORR as assessed by IRRC per RECIST v1.1 criteria.

    Time frame: within approximately 20 months

  5. area under the curve (AUC)

    Area under the curve (AUC) is defined as the area under the plasma concentration versus time curve.

    Time frame: within approximately 20 months

  6. maximum concentration (Cmax)

    Cmax is the highest concentration of a drug in the blood after the drug has been administered and before the administration of a second dose.

    Time frame: within approximately 20 months

  7. time to maximum concentration(Tmax)

    The time it takes for a drug to reach the maximum concentration (Cmax) after administration of the drug

    Time frame: within approximately 20 months

  8. trough concentration (Ctrough)

    Ctrough is the lowest concentration of a drug in the blood after the drug has been administered and before the administration of a second dose.

    Time frame: within approximately 20 months

  9. clearance (CL)

    The clearance is defined as the plasma volume in the vascular compartment that is cleared of drug per unit of time.

    Time frame: within approximately 20 months

  10. volume of distribution (V)

    Volume of distribution (Vd) is defined as the arrangement or rate of incidence of a drug in the body in relation to the measured plasma concentration.

    Time frame: within approximately 20 months

  11. Incidence of anti-drug antibody (ADA)

    Incidence of anti-drug antibody (ADA) is defined as the sum of both treatmentinduced (post-baseline ADA-positive only) and treatment-boosted ADA.

    Time frame: within approximately 20 months

  12. neutralizing antibody (NAb)

    Neutralizing antibodies (NAb) are a subset of binding ADA that bind to the drug and inhibit its pharmacological function by preventing target binding.

    Time frame: within approximately 20 months

07

Study locations

95 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 2, 2024
StartActual
Jun 30, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 31, 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238843
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Jun 30, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arcotatug tavatecan

Start the discussion